Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

QTORIN

Small molecule · developed by Palvella Therapeutics

Phase 3 Most advanced trial
PVLA Developer
1 Registered trials

What is QTORIN?

QTORIN 3.9% Rapamycin Anhydrous Gel is a topical gel containing rapamycin (sirolimus) at 3.9%. It is being studied in microcystic lymphatic malformation, a congenital vascular malformation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Palvella Therapeutics, Inc. (PVLA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06239480 Phase 3 Microcystic Lymphatic Malformation Active not recruiting PVLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Microcystic Lymphatic Malformation

More from Palvella Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PVLA page.

Follow PVLA, the company behind QTORIN

See PVLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PVLA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.